What Researchers Did
Researchers reported safety monitoring data from two randomized double-blind HBOT trials involving 143 military personnel with post-concussive symptoms, receiving either HBOT at 1.5 ATA or sham at 1.2 ATA across 4,245 total chamber sessions.
What They Found
Adverse events were rare: 1.1% of sessions in HOPPS and 2.2% in BIMA. Minor barotrauma (ear pressure effects) was the most common complaint. No serious chamber-related adverse events occurred. The sham control successfully preserved blinding throughout both trials.
What This Means for Canadian Patients
HBOT at 1.5 ATA is very well tolerated. The extremely low serious adverse event rate across thousands of sessions is reassuring for Canadian patients and clinicians considering HBOT for concussion-related symptoms.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study population was entirely US military personnel; adverse event rates may differ in civilian populations with different health profiles or treatment protocols.